Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

28.41 +4.29 (+17.79%)
Streaming Delayed Price Updated: 12:50 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Recap: Eton Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Is NASDAQ:ETON suited for growth investing? ↗
ETON PHARMACEUTICALS INC (NASDAQ:ETON) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
News headline image
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗
ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Why the growth investor may take a look at NASDAQ:ETON. ↗
Exploring ETON PHARMACEUTICALS INC (NASDAQ:ETON)'s growth characteristics. 
Via Chartmill
News headline image
Evaluating NASDAQ:ETON for Growth Investment Opportunities. ↗
Exploring ETON PHARMACEUTICALS INC (NASDAQ:ETON)'s growth characteristics. 
Via Chartmill
News headline image
Eton Pharmaceuticals: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 ↗
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Gilead Sciences Tops Q3 Earnings And Revenue Estimates ↗
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
News headline image
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.